Alder Biopharmaceuticals (ALDR) Stock Rises After Pricing Secondary Offering

NEW YORK (TheStreet) -- Alder Biopharmaceuticals (ALDR) shares are up 0.23% to $45.80 in afternoon trading on Friday after the biotech company announced the pricing of an underwritten public offering of 4,494,382 shares at $44.50 per share.

The company will also give underwriters up to 30-days to purchase an additional 674,157 shares of common stock.

Credit Suisse, Leerink Partners and Wells Fargo Securities  (WFC) are acting as joing book-runners for the offering.

The offering is expected to close June 30.

ALDR Chart ALDR data by YCharts

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Market Signals Change of Direction: Cramer's 'Mad Money' Recap (Monday 9/18/17)

U.S. Concrete, Alder Biopharmaceuticals: 'Mad Money' Lightning Round

Biotech Movers: Impax Shares Jump on FDA Approval for Generic Version of Concerta

Alder BioPharmaceuticals: Cramer's Top Takeaways